Table 4 Response to treatment (N=280)

From: Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer

Response to treatment

ACE (%)

PE (%)

Complete response

25 (18)

36 (26)

Partial response

72 (53)

70 (50)

stable disease

6 (4)

13 (9)

Progressive disease

27 (20)

17 (12)

Toxic death

2 (1)

1 (1)

Not assessable

5 (4)a

3 (2)b

  1. aOne patient died before cycle 1; one had PE; one had XRT following first cycle; one died after cycle 1 due to toxicity not assessed; one stopped after cycle 1 due to toxicity.
  2. bOne patient stopped after cycle 1 due to toxicity not assessed; two lost to FU.
Back to article page